A single head to head trial settled a debate that marketing copy had been dancing around for years. When researchers put semaglutide and tirzepatide against each other directly, one medication produced meaningfully more weight loss than the other after 72 weeks. That doesn’t make the conversation as simple as picking the bigger number, though.
At Lumea Med Spa, semaglutide and tirzepatide questions come up constantly in weight loss consultations. Clients read online that one is “stronger” and assume that settles it, without knowing there are real tradeoffs in side effects, dosing, and cost between the two. This guide breaks down what the actual research shows, so you can have a more informed conversation with your provider.
Two Different Molecules, One Popular Category
Semaglutide and tirzepatide both belong to a class of medications originally developed for type 2 diabetes that turned out to produce significant weight loss as a side effect. Semaglutide is sold under the brand names Ozempic and Wegovy. Tirzepatide is sold as Mounjaro and Zepbound. Both are once weekly injections, and both work by mimicking hormones your gut naturally releases after eating.
Where they differ is in exactly which hormone pathways they target, and that difference turns out to matter more than most people expect.
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1, a hormone that slows digestion, reduces appetite, and helps regulate blood sugar. It was the first medication in this category to reach widespread use for weight management, and it built the clinical evidence base that the entire drug class now stands on.
Our deeper dive into semaglutide for weight loss covers its mechanism, dosing, and results in more detail if you want the full picture on this medication specifically.
How Tirzepatide Works
Tirzepatide takes the same GLP-1 approach and adds a second target. It’s a dual agonist, meaning it activates both GLP-1 and GIP, another gut hormone involved in insulin regulation and appetite. Activating both pathways at once appears to produce a stronger effect on appetite and metabolism than targeting GLP-1 alone.
Tirzepatide received FDA approval for chronic weight management in November 2023, several years after semaglutide had already established itself in this space.
The Head to Head Trial: What SURMOUNT-5 Actually Found
For years, comparisons between the two drugs relied on cross trial comparisons, meaning researchers compared separate studies that weren’t run against each other directly. That changed with a trial called SURMOUNT-5, which randomly assigned 751 adults with obesity to take either tirzepatide or semaglutide at their maximum tolerated dose for 72 weeks.
The results favored tirzepatide by a clear margin. Participants on tirzepatide lost an average of 20.2 percent of their body weight, compared to 13.7 percent for those on semaglutide. Waist circumference dropped further in the tirzepatide group as well. This is the most direct evidence available comparing the two medications under the same study conditions, rather than across separate trials with different populations.
Why the Extra Hormone Pathway Seems to Matter
Researchers believe the added GIP activity in tirzepatide contributes to its stronger results, though the exact biological reasons are still being studied. GIP appears to work alongside GLP-1 to further reduce appetite and may also play a role in how the body processes fat, though this research is still developing.
It’s worth being honest that a group average doesn’t predict your individual result. Some people respond better to semaglutide than the average tirzepatide user, and the reverse is also true. Trial results describe what happened across hundreds of people, not a guarantee for any one person.
Side Effects: Where the Two Actually Differ
Both medications share a similar side effect profile, dominated by gastrointestinal symptoms like nausea, constipation, diarrhea, and occasional vomiting, especially during the first few weeks and after each dose increase. These effects tend to fade as your body adjusts.
Some data suggests tirzepatide’s dual mechanism produces slightly more pronounced gastrointestinal side effects for some patients, though individual experience varies widely. Neither medication is free of side effects, and a slow, careful dose titration is one of the more effective ways to keep them manageable regardless of which drug you choose.
Dosing and Titration: What Starting Treatment Looks Like
Both medications start at a low dose that increases gradually over several weeks or months, rather than jumping straight to the dose used in the major weight loss trials. This slow titration is designed to reduce side effects while your body adjusts to the medication.
Your provider will typically check in every few weeks during this period, adjusting your dose based on how you’re tolerating it and how you’re responding, rather than following a fixed schedule regardless of your experience.
Cost Considerations in Miami
Both medications carry a real cost without insurance coverage, and coverage varies significantly depending on your specific plan and whether your diagnosis qualifies under your policy’s terms. Compounded versions have circulated at lower price points, though these come with their own oversight and quality concerns that are worth discussing directly with your provider before considering them.
Beyond the medication cost itself, factor in the ongoing consultation and monitoring that should come with either treatment. A provider adjusting your dose and watching for side effects is part of what makes this a medical treatment rather than a self directed one.
Who Tends to Do Better on Tirzepatide
Clients focused primarily on maximizing total weight loss, and who are comfortable with a newer medication that has a shorter track record than semaglutide, often lean toward tirzepatide given the SURMOUNT-5 results. It’s also a reasonable option for clients who haven’t responded as strongly as hoped to semaglutide after an adequate trial period.
Who Tends to Do Better on Semaglutide
Semaglutide has a longer real world track record, more long term safety data, and a broader set of FDA approved uses, including cardiovascular risk reduction in certain patients. Clients who value that longer history, or who have cardiovascular risk factors that could benefit from that specific approval, sometimes prioritize semaglutide over tirzepatide’s typically larger average weight loss.
Beyond Weight Loss: Other Approved Uses
Semaglutide, under the brand name Wegovy, received FDA approval in 2024 specifically for reducing the risk of major cardiovascular events in adults with existing heart disease and overweight or obesity, independent of its weight loss effect. Tirzepatide, meanwhile, has its own separate approval for moderate to severe obstructive sleep apnea in adults with obesity.
These distinct approvals reflect genuinely different bodies of research behind each drug, not just marketing differences, and they’re a legitimate factor if you have one of these specific conditions alongside your weight loss goals.
Safety and Who Should Think Twice Before Either One
Neither medication is appropriate for everyone. Both carry warnings related to a personal or family history of certain thyroid cancers, and neither should be used during pregnancy. Anyone with a history of pancreatitis or severe gastrointestinal disease needs a thorough conversation with their provider before starting either drug.
A proper consultation should review your full medical history, current medications, and any conditions that might affect which drug, if either, is appropriate for you. This isn’t a treatment either medication’s manufacturer intends to be self prescribed, and that review matters just as much as picking between the two once you’ve been cleared for either.
What Happens If You Stop Taking Either Medication
Weight regain after stopping either medication is common, since neither drug cures the underlying biology driving weight gain. Most of the appetite suppressing effects fade once the medication clears your system, which is one reason providers increasingly frame these treatments as long term management tools rather than short courses, similar to how blood pressure or cholesterol medication works for many patients.
Combining either medication with the lifestyle habits covered in our guide to medical weight loss versus DIY approaches gives you a better shot at holding onto results if you and your provider eventually decide to taper off.
How Long It Takes to See Meaningful Results
Neither medication produces dramatic changes in the first couple of weeks, since both start at a low dose specifically to minimize side effects while your body adjusts. Most clients notice reduced appetite within the first month, though visible weight loss tends to build gradually over the following several months as the dose increases toward its target level.
The trial data reflects results at 72 weeks, not 72 days. Patience during the early titration period matters, and providers generally discourage judging either medication’s effectiveness until you’ve been on a stable, adequately dosed regimen for at least a few months.
The Role of Nutrition and Movement Alongside Either Medication
Neither semaglutide nor tirzepatide works in isolation from the rest of your habits, even though the appetite suppression can make it feel that way at first. Reduced hunger makes it easier to eat less, but the actual nutritional quality of what you do eat still affects your energy levels, muscle preservation, and how sustainable your results are.
Resistance training in particular deserves attention on either medication, since a portion of the weight lost on GLP-1 and GIP therapies comes from lean muscle mass rather than fat alone. Providers increasingly recommend pairing either medication with regular strength training specifically to help protect muscle while the number on the scale moves in the direction you want.
How to Actually Decide Between the Two
Start with your specific health profile and goals rather than the SURMOUNT-5 headline number alone. If you have cardiovascular disease alongside excess weight, semaglutide’s specific approval for that population is worth discussing. If you have obstructive sleep apnea, tirzepatide’s approval there is relevant. If neither applies and your main goal is maximizing weight loss with an FDA approved medication, the head to head data favors tirzepatide, though your individual response and tolerance still matter more than the average.
Our weight loss program combines whichever medication fits your profile with the monitoring and lifestyle support that actually determines how well either one works long term. Some clients also add Lipolean B12 injections to support energy and metabolism alongside their primary treatment.
What This Looks Like at Lumea
At Lumea Med Spa, a weight loss consultation starts with your labs, your health history, and an honest conversation about your goals, not a decision made before you’ve even sat down. Our Kendall and Dadeland team will walk you through both options, including where the research actually supports one over the other and where it comes down to your personal fit.
Schedule a consultation with our Miami team to find out which medication, and which overall plan, actually makes sense for you.
Frequently Asked Questions About Semaglutide vs Tirzepatide
Is tirzepatide always more effective than semaglutide?
On average, yes, based on the SURMOUNT-5 head to head trial, which found tirzepatide produced greater weight loss over 72 weeks. Individual results vary, and some people respond better to semaglutide specifically.
Can I switch from semaglutide to tirzepatide if it’s not working for me?
Many clients do switch after an adequate trial period on one medication hasn’t produced the expected results. Your provider will typically want to see a genuine trial at an appropriate dose before making that call.
Which one has worse side effects?
Both share a similar gastrointestinal side effect profile. Some data suggests tirzepatide may cause slightly more pronounced symptoms for some patients, though a slow dose increase helps manage this with either medication.
Do I have to stay on these medications forever?
Not necessarily, but weight regain after stopping is common for most people, since the underlying biology driving weight gain doesn’t change. Many providers now treat these as long term management medications rather than short courses, similar to other chronic condition treatments.
Sources
Eli Lilly and Company, “FDA Approves Lilly’s Zepbound (tirzepatide) for Chronic Weight Management”: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight
American College of Cardiology, “SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide”: https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2025/07/10/09/09/SURMOUNT-5
Yale Medicine, “Why Your Cardiologist May Prescribe Semaglutide (Wegovy)”: https://www.yalemedicine.org/news/why-your-cardiologist-may-prescribe-semaglutide-wegovy
